Dr. Mohammad A. Mahmud, MD, MPH, PHD
Internal Medicine (Internal Medicine Physician)
703 Magnolia Ave
Corona, CA 92879
Who else practices at this address →
Riverside County includes primary care (1% of residents) and mental health (5% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 274
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A70230 (first issued 1999; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Desert Medical Group Inc (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 274
- Services billed
- 800
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 244 | 212 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 68 | 16 |
| Injection of drug or substance under skin or into muscle | 52 | 36 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 52 | 52 |
| Injection, ketorolac tromethamine, per 15 mg | 49 | 24 |
| Urinalysis, manual test | 46 | 42 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 28 | 28 |
| New patient office or other outpatient visit, 15-29 minutes | 24 | 24 |
| Blood test, comprehensive group of blood chemicals | 17 | 17 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Corona, CA | 206 |
| Methylprednisolone Other prescribers in Corona, CA | 200 |
| Baclofen Other prescribers in Corona, CA | 126 |
| Meloxicam Other prescribers in Corona, CA | 116 |
| Doxycycline Hyclate Other prescribers in Corona, CA | 109 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Corona, CA | 99 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Corona, CA | 84 |
| Tramadol Hcl Other prescribers in Corona, CA | 66 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Corona, CA | 60 |
| Cefdinir Other prescribers in Corona, CA | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 1 companies. The companies reported $60,636 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie Inc. · Completed · NCT05652205 - M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation
AbbVie Inc. - A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
AbbVie Inc. · Completed · NCT05760313 - Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
AbbVie Inc. · Completed · NCT03339128 - Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
AbbVie Inc. - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie Inc. · Completed · NCT04166058 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
AbbVie Inc. · Completed · NCT04026113 - M21-862 - A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
AbbVie Inc. - A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
AbbVie Inc. · Enrolling by invitation · NCT04880876
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.